Health ❯ Healthcare ❯ Oncology

Lung Cancer

Non-Small Cell Lung Cancer Small Cell Lung Cancer ALK-positive NSCLC Biomarker Testing EGFR-Mutated Non-Small Cell Lung Cancer Lung Squamous Cell Carcinoma Immunotherapy Clinical Trials EGFR-Mutated NSCLC Non-small Cell Lung Cancer

FDA Grants Priority Review to Ifinatamab Deruxtecan for Pretreated Small Cell Lung Cancer

Real-Time Oncology Review and Project Orbis will speed and coordinate evaluation of the B7-H3 antibody–drug conjugate.

Summit Therapeutics Shares Rally as Ivonescimab Trials Near Q2 Readout

Morning Immunotherapy Boosts Survival in Lung Cancer Trial

Treating Advanced Lung Cancer Before 3 p.m. Extends Survival in Phase III Trial

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

Immunotherapy Before 3 p.m. Linked to Longer Survival in Small Cell Lung Cancer

Junshi’s Subcutaneous Toripalimab Matches IV in Phase 3 NSCLC Trial as Company Prepares NDA

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

CRISPR Knockout of NRF2 Reverses Chemotherapy Resistance in Lung Cancer Models

Lung Cancer Survival Climbs With Earlier Detection as ALA Flags Threats to Progress

Rome Hospital Reports World's First Pulmonary Artery Transplant for Lung Cancer

Final FLAURA2 Data Show Osimertinib Plus Chemotherapy Extends Survival in EGFR-Mutant Lung Cancer

EU Regulators Back Libtayo as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC

Robotic Bronchoscopy With Cone-Beam CT Achieves 85% Diagnostic Yield in Trial

EML4-ALK V3 Proves More Aggressive and Less Drug-Sensitive Than V1 in New Study

Once-Monthly Subcutaneous Amivantamab Plus Lazertinib Shows High Response in Untreated EGFR‑Mutated NSCLC

3-Week Radiotherapy Regimen Matches Survival, Cuts Severe Toxicity in Limited-Stage SCLC Trial

WCLC 2025: Combination Approaches Redraw EGFR-Mutant NSCLC Care